Burkina FasoTuberculosis profile
Population  2015 18 million
Estimates of TB burden*, 2015 Number (thousands) Rate
(per 100 000 population)
Mortality (excludes HIV+TB) 1.6 (0.97–2.4) 9 (5.4–14)
Mortality (HIV+TB only) 0.27 (0.12–0.48) 1.5 (0.67–2.7)
Incidence  (includes HIV+TB) 9.4 (6.1–13) 52 (34–74)
Incidence (HIV+TB only) 0.89 (0.57–1.3) 4.9 (3.2–7.1)
Incidence (MDR/RR-TB)** 0.4 (0.018–0.77) 2.2 (0.1–4.3)
Estimated TB incidence by age and sex (thousands)*, 2015
  0-14 years > 14 years Total
Females 0.61 (0.33–0.89) 2.2 (0.24–4.2) 2.8 (0.58–5.1)
Males 0.44 (0.26–0.61) 6.1 (4.2–8) 6.6 (4.5–8.7)
Total 1 (0.67–1.4) 8.3 (6.3–10) 9.4 (6.1–13)
TB case notifications, 2015  
Total cases notified 5 808
Total new and relapse 5 594
          - % tested with rapid diagnostics at time of diagnosis 2%
          - % with known HIV status 97%
          - % pulmonary 85%
          - % bacteriologically confirmed among pulmonary 84%
Universal health coverage and social protection  
TB treatment coverage (notified/estimated incidence), 2015 60% (42–92)
TB patients facing catastrophic total costs  
TB case fatality ratio (estimated mortality/estimated incidence), 2015 0.21 (0.11–0.36)
TB/HIV care in new and relapse TB patients, 2015 Number (%)
Patients with known HIV-status who are HIV-positive 504 9%
          - on antiretroviral therapy 427 85%
Drug-resistant TB care, 2015 New cases Previously treated
cases
Total
number***
Estimated MDR/RR-TB cases among notified
pulmonary TB cases
  220
(28–420)
Estimated % of TB cases with MDR/RR-TB 2.8% (0.1–6.7) 21% (2.2–39)  
% notified tested for rifampicin resistance 2% 38% 283
MDR/RR-TB cases tested for resistance to second-line drugs   20
Laboratory-confirmed cases MDR/RR-TB: 54, XDR-TB: 0
Patients started on treatment **** MDR/RR-TB: 36, XDR-TB: 0
Treatment success rate and cohort size Success Cohort
New and relapse cases registered in 2014 81% 5 322
Previously treated cases, excluding relapse, registered in 2014 75% 456
HIV-positive TB cases, all types, registered in 2014 74% 564
MDR/RR-TB cases started on second-line treatment in 2013 62% 42
XDR-TB cases started on second-line treatment in 2013   0
TB preventive treatment, 2015  
% of HIV-positive people (newly enrolled in care) on preventive treatment  
% of children (aged < 5) household contacts of bacteriologically-confirmed
TB cases on preventive treatment
 
TB financing, 2016  
National TB budget (US$ millions) 9.7
Funding source: 3% domestic, 16% international, 81% unfunded
* Ranges represent uncertainty intervals
** MDR is TB resistant to rifampicin and isoniazid; RR is TB resistant to rifampicin
*** Includes cases with unknown previous TB treatment history
**** Includes patients diagnosed before 2015 and patients who were not laboratory-confirmed
***
(Rate per 100 000 population per year)
Mortality graph
   Mortality  (excludes HIV+TB)

(Rate per 100 000 population per year)
Incidence graph
   Incidence
   Notified (new and relapse)
   Incidence (HIV+TB only)

Notified cases by age group and sex, 2015
age_sex_graph
____
FemalesMales

Treatment success rate (%)
tx success graph
   
New and relapse
   Retreatment, excluding relapse
   HIV-positive   MDR/RR-TB   XDR-TB

Total budget (US$ millions)
Budget funding Graph
__Unfunded
__Funded internationally
__Funded domestically
 
 Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in consultation with countries.
 Generated: 2016-12-11 Data: www.who.int/tb/data